Who we are

Who we are

We are a clinical stage immunology and inflammation focused company developing novel gene therapies and biologics and applying a systems approach to creating rational combination therapies that can significantly improve patients lives  

Leadership

Clement Leong, PhD, MBA
Chief Executive Officer and Director

Dr Leong has a pharma/biotech and venture capital background in Australia and the United States (Schering Plough Biopharma/DNAX, Entelos, SciVentures Investments), and over 20 years of experience and in leading financings and therapeutic/device development programs.

Dr Leong received his PhD (Medicine) from the University of Western Australia and his MBA from the Australian Graduate School of Management.

Geoffrey Pietersz, PhD
Vice President, Technology Development

Dr Pietersz has over 30 years of experience in the development of immunotherapies, gene therapies, engineered biologics and small molecule inhibitors at Prima Biomed, 4G Vaccines, IgaVax, Avipep, Ascend Biopharma, and EnVision Sciences. He is Professor at the Baker Institute.

Dr Pietersz received his PhD from the University of Melbourne.

Jacqui Waterkeyn, PhD
Vice President, Clinical Operations and Regulatory Affairs

Dr Waterkyn has more than 25 years of regulatory affairs, clinical operations, and product development experience in the biotech and pharma sectors, including as the sponsor for a phase 1 unit (10 years at Nucleus Network), in contract research organisations and investigator-initiated trials. She has held operational and project oversight of more than 100 commercial and academic trials across multiple therapeutic areas.

Dr Waterkyn received her PhD from the University of Melbourne.

Satish Menon, PhD
Vice President, Chemistry, Manufacturing and Controls (CMC)

Dr Menon has over 30 years of experience in process development and manufacture, including in roles as Technology Officer at Object Pharma and Allergan, Senior Consultant at PVP Biologicals and Senior Technology Consultant at Seq-Biomarque LLC. He has led and advised GMP development and manufacture of 10 biologics/gene therapies, from preclinical to Phase 3.

Dr Menon received his PhD in Biochemistry from the Indian Institute of Science and undertook his postdoctoral training at Harvard Medical School.

Board

Jacques Banchereau, PhD
Non-Executive Director

Dr Banchereau is currently the Director of Immunological Sciences and the Deputy Director at JAX Genomic Medicine. He was formerly Chief Scientific Officer at Hoffmann-La Roche (Roche) and Director of the Baylor Institute for Immunology Research in Dallas, Texas.

Dr Banchereau received his PhD from the University of Paris.

Edward McKenna, PharmD
Non-Executive Director

Dr McKenna recently retired from Genentech, Inc. after 18 years of service. He was formerly Principal Medical Science Director in US Medical Affairs and Medical Partner/Lead for the Skin Cancer Franchise. He has held positions at Roche and Genentech, Inc, where he led medical teams for colorectal cancer, gastric cancer and breast cancer as well as serving as a Medical Science Liaison for gastrointestinal and breast cancer.

Dr McKenna received his PhD from the University of Kentucky.

Andrew Strong, JD
Non-Executive Director

Currently a partner at Pillsbury Winthrop Shaw Pittman law firm, Mr Strong has extensive experience in life sciences and routinely advises on corporate and securities, mergers and acquisitions, and private and public financing. He is the founding President and Chief Executive Officer of Kalon Biotherapeutics.

Mr Strong received his JD from the South Texas College of Law and his BS (Civil Engineering) from Texas A&M University.

Michael Derby, MS, MBA
Non-Executive Director

Mr. Derby is the Founder and Managing Partner at TardiMed Sciences, a company creation and investment firm in the life sciences space. He is a successful entrepreneur, investor and operating executive, having founded, led and exited a number of startup companies developing important biopharmaceutical products. He previously held commercial roles at Merck & Co. and Forest Laboratories, and served as a venture capitalist for several years investing in biopharmaceutical and medical technology companies.

Mr. Derby received an MS from the University of Rochester School of Medicine and Dentistry and an MBA from New York University’s Stern School of Business.

Advisors

George J. Hruza, MD MBA

Dr Hruza is an Adjunct Professor of Dermatology and Otolaryngology at St Louis University. He received his medical degree from New York University, his MBA from Washington University and completed his dermatology residency at New York University Medical Center. This was followed by a laser surgery fellowship at Harvard Medical School and a Mohs and dermatologic surgery fellowship at the University of Wisconsin-Madison. Before his current position, he was an Associate Professor of Dermatology, Surgery and Otolaryngology and Director of Dermatologic Surgery training at Washington University in St Louis. He currently serves on the American Society for Laser Medicine and Surgery Board of Directors, is President of the Missouri State Medical Association and is immediate Past President of the American Academy of Dermatology. He has contributed more than 180 publications to the medical literature.

John Lear, MB ChB MD FRCCP(UK)

Dr John Lear is consultant dermatologist at BMI The Alexandra Hospital and his NHS practices, Manchester Royal Infirmary and Hope Hospital. His main interest is the diagnosis and management of skin cancer with a particular interest in the surgical and non-surgical management of these conditions. Having qualified in Medicine in 1991 at Leicester University, Dr Lear underwent general medical training in the Midlands and dermatological training in the Midlands and the South West. He has published over 100 papers on the genetics, epidemiology, diagnosis and therapy of skin cancer. He is chair of the specialist skin cancer MDT meeting for Greater Manchester, is a member of the NCRI Nonmelanoma Skin Cancer study group and the NCIN Skin Cancer subgroup and a founding member of the British Society for Skin Care in Immunocompromised individuals.

Sherrif F. Ibrahim, MD, PhD

Dr Ibrahim is a board-certified dermatologist and a fellow of the American College of Mohs surgery, the American Academy of Dermatology, and the American Society for Dermatologic Surgery. He is the founder of Rochester Dermatologic Surgery and an Associate Professor of Dermatology at the University of Rochester Medical Center. He completed his undergraduate education at the Massachusetts Institute of Technology and received both his MD and PhD degrees from the University of Washington. He undertook his residency training at the University of Rochester, followed by a fellowship in Mohs surgery, facial reconstruction, laser surgery and cosmetic dermatology at the University of California, San Francisco.

Gregory Siller, MBBS FACD

Dr Siller is an Associate Professor (Adjunct) of The University of Queensland and Practice Principal of Central Brisbane Dermatology. He is a senior visiting consultant dermatologist at The Princess Alexandra Hospital where he currently conducts multidisciplinary clinics for high risk transplant recipients. He brings over 20 years of experience in early phase clinical trials especially in the field of emerging non-surgical therapies for skin cancer and has been the lead investigator for the initial trials of ASN 002 in basal cell carcinoma. Awarded a Presidential Citation by the Australasian College of Dermatologists in recognition of his contributions, Dr Siller has also been a consultant to successful start-ups and multiple pharmaceutical companies. He also has a long standing interest in lasers and allergy patch testing.